University of California, Los Angeles

KarXT, a new antipsychotic targeting muscarinic receptors, received US approval, offering potential for more effective and better-tolerated schizophrenia treatment. It modulates dopamine release and improves cognitive function without severe side effects, marking a shift in psychosis treatment. Future drugs may further refine this approach, tailoring treatment to individual needs.

Nomic and PICI collaborate to profile ~3000 blood samples from RADIOHEAD study using nELISA™ to understand immunotherapy responses, aiming to improve patient care through precision medicine.

A. Lenore Ackerman discusses the potential use of oral sulopenem for uncomplicated UTIs, emphasizing its role in high-risk patients with multi-drug-resistant infections, cautioning against its broad use due to concerns over resistance development.

Recent cancer research breakthroughs include Oncolytics Biotech's BRACELET-1 study showing promising results for pelareorep in HR+/HER2- breast cancer, Novartis AG's FDA approval of Kisqali for early-stage breast cancer, Lantheus Holdings' positive Phase 3 SPLASH trial results for 177Lu-PNT2002 in prostate cancer, Sutro Biopharma's encouraging Phase 1b study data for Luvelta in ovarian cancer, and Zymeworks' upcoming presentation of preclinical data on its antibody-drug conjugate programs.

FDA approves Kisqali for early-stage HR-positive, HER2-negative breast cancer, reducing recurrence risk by 25% when taken with aromatase inhibitors for 3 years.

FDA approves Novartis’ Kisqali for early breast cancer at high risk of recurrence, including node-negative disease, potentially adding $3B to annual sales. Kisqali now covers a broader population than competitor Lilly’s Verzenio. Based on NATALEE trial results, Kisqali plus endocrine therapy showed a 25.1% reduction in recurrence risk.

Novartis’ Kisqali (ribociclib) approved by FDA for early breast cancer treatment in combination with an aromatase inhibitor for HR-positive/HER2-negative stage 2 and 3 patients at high risk of recurrence. Supported by NATALEE trial results showing reduced recurrence risk by 25.1% with Kisqali plus endocrine therapy versus endocrine therapy alone, with benefits extending beyond three years.

FDA approves Kisqali (ribociclib) for HR+/HER2- stage II and III early breast cancer, reducing recurrence risk by 25% with endocrine therapy. NATALEE trial results show consistent benefits and well-tolerated safety profile across subgroups, including node-negative patients. Kisqali is under regulatory review worldwide.

The FDA approved Kisqali with an aromatase inhibitor for postsurgical treatment of HR-positive, HER2-negative early breast cancer at high risk of recurrence. The efficacy was demonstrated in the phase 3 NATALEE trial, showing improved invasive disease-free survival. Side effects included neutropenia, liver-related issues, QT interval prolongation, and interstitial lung disease/pneumonitis.

The FDA approved adjuvant ribociclib (Kisqali) plus an aromatase inhibitor for HR-positive, HER2-negative stage II and III early breast cancer with high recurrence risk, based on NATALEE trial data showing improved invasive disease-free survival. The combination achieved 3-year iDFS rates of 90.4% vs 87.1% with endocrine therapy alone, with benefits sustained over 44.2 months of follow-up.